Research programme: LFA-1 antagonists - ICOS

Drug Profile

Research programme: LFA-1 antagonists - ICOS

Latest Information Update: 22 Apr 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ICOS Corporation
  • Class Small molecules
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 22 Apr 2009 No development reported - Preclinical for Psoriasis in USA (PO)
  • 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly
  • 06 Jun 2003 ICOS Corporation and Biogen have concluded their LFA-1 programme collaboration, with ICOS acquiring sole development and marketing rights to the programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top